Poolbeg Pharma (LON:POLB – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported GBX (0.28) EPS for the quarter, Digital Look Earnings reports.
Poolbeg Pharma Stock Up 0.7%
Shares of Poolbeg Pharma stock opened at GBX 7.40 on Tuesday. The company has a market cap of £56.49 million, a price-to-earnings ratio of -7.87 and a beta of 1.83. The company’s 50 day moving average is GBX 8.01 and its 200 day moving average is GBX 6.42. Poolbeg Pharma has a twelve month low of GBX 3.30 and a twelve month high of GBX 9.30.
Analysts Set New Price Targets
Separately, Shore Capital Group reaffirmed a “house stock” rating on shares of Poolbeg Pharma in a research report on Thursday, September 24th.
About Poolbeg Pharma
Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.
Further Reading
- Five stocks we like better than Poolbeg Pharma
- MongoDB Stock Drops 17% After CEO Exit—What Investors Should Know
- Bernstein Downgrades 3 Cybersecurity Stocks: How Concerned Should Investors Be?
- Six Flags Launches FlexPay—Is There Any FUN Left in the Stock?
- Brewing Trouble? Starbucks Spills the Beans on 250 Store Closures
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
